Research programme: cardiac regeneration therapies - ChemRegen/Human BioMolecular Research Institute/Sanford-Burnham Medical Research Institute

Drug Profile

Research programme: cardiac regeneration therapies - ChemRegen/Human BioMolecular Research Institute/Sanford-Burnham Medical Research Institute

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemRegen; Human BioMolecular Research Institute; Sanford Burnham Prebys Medical Discovery Institute
  • Class Cell therapies; Heart failure therapies
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Heart failure

Highest Development Phases

  • Research Heart failure

Most Recent Events

  • 01 Aug 2016 Early research is underway in the US
  • 01 Aug 2016 Research programme: cardiac regeneration therapies - ChemRegen/Human BioMolecular Research Institute/Sanford-Burnham Medical Research Institute is available for licensing as of 01 Aug 2016. http://chemregen.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top